- Home
- J vs RPRX Comparison
J vs RPRX Comparison
Compare J & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | J | RPRX |
|---|---|---|
| Founded | 1947 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | J | RPRX |
|---|---|---|
| Price | $134.79 | $38.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $155.90 | $46.00 |
| AVG Volume (30 Days) | 1.4M | ★ 4.0M |
| Earning Date | 11-20-2025 | 11-05-2025 |
| Dividend Yield | 0.95% | ★ 2.30% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | 1.75 |
| Revenue | ★ $12,029,783,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.13 |
| Revenue Next Year | $6.38 | $1.48 |
| P/E Ratio | $56.75 | ★ $21.84 |
| Revenue Growth | ★ 4.60 | 3.70 |
| 52 Week Low | $106.23 | $24.05 |
| 52 Week High | $168.44 | $41.24 |
Technical Indicators
Market Signals| Indicator | J | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 46.84 |
| Support Level | $132.75 | $39.24 |
| Resistance Level | $143.16 | $39.88 |
| Average True Range (ATR) | 5.05 | 0.89 |
| MACD | 0.46 | -0.24 |
| Stochastic Oscillator | 35.29 | 34.95 |
Price Performance
Historical ComparisonAbout J Jacobs Solutions Inc.
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.